期刊
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
卷 27, 期 2, 页码 453-456出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1078155220929967
关键词
Nivolumab; papillary thyroid; partial response; immune checkpoint inhibitor; metastatic thyroid cancer
Immune checkpoint inhibitors have shown promising effects in the treatment of hepatocellular carcinoma and papillary thyroid carcinoma, suggesting the need for further studies in this area.
Introduction Clinical indications of immune checkpoint inhibitors have expanded to a variety of malignancies. Approximately one in six patients with hepatocellular carcinoma respond to programmed death 1 inhibitors nivolumab and pembrolizumab. Case report We report herein a patient with synchronous metastatic hepatocellular carcinoma and advanced papillary thyroid carcinoma treated with nivolumab in the second-line therapy. Management and outcome: The hepatocellular carcinoma showed a durable response to the second-line agent nivolumab. Remarkably, the patient's papillary thyroid carcinoma also responded to this programmed death 1 inhibitor. Discussion To our knowledge, this is the first case report showing the efficacy of nivolumab in the treatment of metastatic papillary thyroid carcinoma. Further studies with immune checkpoint inhibitors in papillary thyroid carcinoma seem warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据